Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Company Overview

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories. Its portfolio has included treatments such as Rytary, a carbidopa and levodopa product for Parkinson’s disease, as well as products for thyroid disorders and other conditions.

The company was formed in 2017 through the combination of Amneal Pharmaceuticals, founded by brothers Chirag Patel and Chintu Patel, and Impax Laboratories. Amneal is headquartered in Bridgewater, New Jersey, and maintains research, development and manufacturing operations in the United States and India. Its products are marketed in the United States and selected international markets. Chirag Patel and Chintu Patel have served as the company’s co-chief executive officers.

Key Stats

• Today's Range: $19.53 to $19.92
• 50-Day Range: $16.65 to $20.50
• 52-Week Range: $9.56 to $21.17
• Volume: 552,006 shs
• Average Volume: 2.23 million shs
• Market Capitalization: $6.33 billion
• P/E Ratio: 40.50
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

Amneal Pharmaceuticals Stock Analysis - MarketRank™

Amneal Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 318th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Amneal Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amneal Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 13.68%

Earnings Growth

Earnings for Amneal Pharmaceuticals are expected to grow by 13.68% in the coming year, from $0.95 to $1.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amneal Pharmaceuticals is 40.26, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amneal Pharmaceuticals is 40.26, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.59.

Price to Earnings Growth Ratio

Amneal Pharmaceuticals has a PEG Ratio of 2.31. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.27% of the float of Amneal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 6.64.

Change versus previous month

Short interest in Amneal Pharmaceuticals has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amneal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amneal Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.38

News Sentiment

Amneal Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Amneal Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

9 people have searched for AMRX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

5 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,216,567.00 in company stock.

Percentage Held by Insiders

17.30% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMRX
• Previous Symbol: NASDAQ:AMRX
• CIK: 1723128
• Web: amneal.com
• Phone: 908-947-3120
• Fax: 908-947-3146
• Employees: 8,500
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Amneal Pharmaceuticals: $21.00
• High Price Target: $27.00
• Low Price Target: $13.00
• Potential Upside/Downside: +5.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.49
• Trailing P/E Ratio: 40.50
• Forward P/E Ratio: 20.87
• P/E Growth: 2.31
• Net Income: $72.06 million
• Net Margins: 5.05%
• Pretax Margin: 6.45%
• Return on Equity: -584.46%
• Return on Assets: 7.78%

Debt

• Debt-to-Equity Ratio: 77.65
• Current Ratio: 2.20
• Quick Ratio: 1.44

Sales & Book Value

• Annual Sales: $3.12 billion
• Price / Sales: 2.03
• Cash Flow: $1.58 per share
• Price / Cash Flow: 12.58
• Book Value: ($0.23) per share
• Price / Book: -86.20

Miscellaneous

• Outstanding Shares: 319,354,000
• Free Float: 264,106,000
• Market Cap: $6.33 billion
• Optionable: Optionable
• Beta: 1.22